3.93
+0.13(+3.42%)
Currency In USD
| Previous Close | 3.8 |
| Open | 3.82 |
| Day High | 3.98 |
| Day Low | 3.79 |
| 52-Week High | 4.22 |
| 52-Week Low | 0.75 |
| Volume | 841,874 |
| Average Volume | 4.6M |
| Market Cap | 353.45M |
| PE | -4.18 |
| EPS | -0.94 |
| Moving Average 50 Days | 2.72 |
| Moving Average 200 Days | 1.36 |
| Change | 0.13 |
If you invested $1000 in Chimerix, Inc. (CMRX) 10 years ago, it would be worth $104 as of February 05, 2025 at a share price of $3.93. Whereas If you bought $1000 worth of Chimerix, Inc. (CMRX) shares 5 years ago, it would be worth $2,195.53 as of February 05, 2025 at a share price of $3.93.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Chimerix to Present at JonesTrading Virtual Precision Medicine Symposium
GlobeNewswire Inc.
Jan 29, 2025 9:15 PM GMT
DURHAM, N.C., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mi
Chimerix to Speak Today at The White House Cancer Moonshot Forum
GlobeNewswire Inc.
Jan 13, 2025 12:00 PM GMT
Chief Scientific Officer, Joshua E. Allen, Ph.D. to Highlight Cancer Moonshot’s Impact on Brain Cancer and Rare Pediatric Disease Drug DevelopmentDURHAM, N.C., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company w
Chimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma
GlobeNewswire Inc.
Dec 30, 2024 12:00 PM GMT
Secures Access of Up To $30 Million to Support Potential Launch Through Silicon Valley Bank Credit FacilityDURHAM, N.C., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines